Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 5,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Hyperlipidemia, Type 2 Diabetes
Interventions: ETC-1002, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Pneumonia
Interventions: Amikacin (BAY41-6551), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 7
States / cities: Birmingham, Alabama • Melbourne, Florida • Albany, New York + 4 more

Conditions: Cognitive Deficits in Schizophrenia
Interventions: ABT-126, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 20 Years to 55 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 23
States / cities: Cerritos, California • Costa Mesa, California • Escondido, California + 19 more

Conditions: Phobic Disorders
Interventions: JNJ-42165279, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 13
States / cities: La Jolla, California • Hartford, Connecticut • Orlando, Florida + 10 more

Conditions: Atrial Fibrillation
Interventions: sphygmomanometer cuff inflations, standard of care; Other
Lead sponsor: Baystate Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Rotator Cuff Tendinopathy
Interventions: Secukinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Westlake Village, California • Miami, Florida • Plantation, Florida + 3 more

Conditions: Inflammation, Crohn's Disease
Interventions: NNC 0142-0000-0002, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 16
States / cities: Anaheim, California • Lakewood, Colorado • Chicago, Illinois + 13 more

Conditions: Physical Activity, Fatigue
Interventions: Tai Chi; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 60 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Spontaneous Urticaria (CSU)
Interventions: Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 121
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more

Conditions: Major Depressive Disorder
Interventions: AZD6765, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 27
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 24 more

Conditions: Infections, Meningococcal
Interventions: MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine; Combination Product · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 50 Years
Enrollment: 1,440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more

Conditions: Bullous Pemphigoid
Interventions: dupilumab, Matching Placebo, Oral corticosteroids (OCS); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 15
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 12 more

Conditions: Fabry Disease
Interventions: Lucerastat, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 17
States / cities: Birmingham, Alabama • Irvine, California • Oakland, California + 14 more

Conditions: Moderate to Severe Atopic Dermatitis
Interventions: Rezpegaldesleukin, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 28
States / cities: Bryant, Arkansas • Fountain Valley, California • Los Angeles, California + 22 more

Conditions: Epilepsy With Partial-onset Seizures
Interventions: Lacosamide, Placebo; Drug · Other
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 1 Month to 47 Months
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 7
States / cities: Birmingham, Alabama • Tampa, Florida • Henderson, Nevada + 3 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: RO6889450, Placebo, Risperidone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 24
States / cities: Little Rock, Arkansas • Bellflower, California • Culver City, California + 20 more

Conditions: Schizophrenia
Interventions: BI 425809, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 28
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Encino, California + 24 more

Conditions: Chronic Migraine
Interventions: LBR-101 High Dose, LBR-101 Low Dose, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 57
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 51 more

Conditions: Myofascial Pain Syndromes, Myofascial Trigger Point Pain, Trigger Point Pain, Myofascial
Interventions: OnabotulinumtoxinA, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Cleveland, Ohio • Mayfield Heights, Ohio • Westlake, Ohio

Conditions: Insomnia
Interventions: Lemborexant, Lemborexant-matched placebo, Zolpidem tartrate, Zolpidem-matched placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 1,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 60
States / cities: Jasper, Alabama • Glendale, Arizona • Little Rock, Arkansas + 49 more

Conditions: Chronic Rhinosinusitis
Interventions: OPN-375; Drug
Lead sponsor: Optinose US Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 46
States / cities: Gilbert, Arizona • Bakersfield, California • Folsom, California + 40 more

Conditions: Asthma
Interventions: Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Placebo Inhaltion Powder; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Bell Gardens, California • Huntington Beach, California • Long Beach, California + 19 more

Conditions: Malaria, Vivax
Interventions: Tafenoquine 150 mg, Matched placebo 150mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 486 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Glendale, California • Overland Park, Kansas • Baltimore, Maryland

Conditions: Crohn's Disease
Interventions: Placebo, ABT-874; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 36
States / cities: Orange, California • San Diego, California • Hamden, Connecticut + 30 more

Search by objective public record fields.

A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS)

Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

Effect of Remote Ischemic Preconditioning on Incidence of Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery

Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

UCLA Tai Chi in a Community Setting Study

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

AZD6765 Severe Major Depressive Disorder (MDD) IV

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid

Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

Assessment of LBR-101 In Chronic Migraine

Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic Pain

Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps

Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)

Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease